TrialESMO open2026

TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.

S Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.